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Why are lupus patients at increased 
risk for cardiovascular disease?
Patients with systemic lupus erythematosus (SLE) 
have accelerated atherosclerosis; it is estimated that 
premenopausal SLE patients have a 50-times-greater risk 
of a fatal vascular event as compared with control subjects. 
The underlying mechanisms are poorly understood, and 
research has been hampered by a lack of animal models. 
In a study by Stanic et al., a chimeric animal model of 
lupus cardiovascular disease was created by transfer of 
bone marrow from lupus-susceptible mice to lethally 
irradiated low-density lipoprotein (LDL) receptor-defi cient 
(LDLr–/–) mice, an established model of atherosclerosis. 
These mice developed a lupus-like disease characterized 
by production of double-stranded DNA autoantibodies 
and renal disease. A Western-type diet caused increased 
mortality and atherosclerotic lesions. Also, the plaques were 
highly infl ammatory and contained more CD3+ T cells than 
those of controls. Increased activation of CD4+ T and B 
cells and signifi cantly higher antibody against oxidized LDL 
and cardiolipin were also noted. These results demonstrate 
that the lupus-susceptible immune system enhances 
atherogenesis and modulates plaque composition, and they 
may explain the increased susceptibility to cardiovascular 
disease in young lupus patients. (Proc Natl Acad Sci USA 
2006; 103: 7018–7023)
Jai Radhakrishnan
Important role for bradykinin B2 
receptors
Genetically determined higher levels of angiotensin-
converting enzyme (ACE), which do not signifi cantly affect 
blood pressure or angiotensin II and aldosterone levels, 
have been correlated with an increased risk of diabetic 
nephropathy, breast cancer, Alzheimer’s disease, Parkinson’s 
disease, congestive heart failure, myocardial infarction, and 
stroke. Conversely, inhibitors of the enzyme (ACEIs) have 
benefi cial effects beyond those attributable to changes in 
blood pressure in conditions such as diabetic nephropathy 
and coronary artery disease. In agreement with the human 
studies, mice with one, two, or three copies of the Ace gene and 
proportional plasma ACE levels have indistinguishable blood 
pressure and similar angiotensin II levels. Yet, when these mice 
are made diabetic, the animals with three Ace genes develop 
markedly worse kidney function. This and other observations 
suggest that modest changes in ACE levels affect the levels 
of its substrates much more than the levels of its products, 
and that the ACE substrate hormone bradykinin may play an 
important role in disease progression.
Recently, it was shown that mice that are diabetic because 
of a dominant mutation (Akita) in the Ins2 gene and 
also lack the bradykinin B2 receptor develop more severe 
kidney disease than their diabetic littermates that have 
the B2 receptor. Kakoki et al. now report that this action 
is only part of the mechanism of disease. Diabetes and the 
absence of the B2 receptor enhance senescence-associated 
phenotypes in multiple tissues. Thus, at 12 months of age, 
indicators of senescence (alopecia, skin atrophy, kyphosis, 
osteoporosis, testicular atrophy, lipofuscin accumulation 
in renal proximal tubule and testicular Leydig cells, and 
apoptosis in the testis and intestine) are virtually absent in 
wild-type mice, detectable in B2 receptor-null mice, clearly 
apparent in mice diabetic because of a dominant mutation 
(Akita) in the Ins2 gene, and most obvious in Akita diabetic 
plus B2 receptor-null mice. Renal expression of several 
genes that encode proteins associated with senescence 
and/or apoptosis (TGFβ1, connective tissue growth factor, 
p53, α-synuclein, and forkhead box O1) increases in the 
same progression. Concomitant increases occur in 8-
hydroxy-2′-deoxyguanosine, point mutations and deletions 
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in kidney mitochondrial DNA, and thiobarbituric acid-
reactive substances in plasma, but decreases occur in the 
reduced form of glutathione in erythrocytes. Thus, absence 
of the bradykinin B2 receptor also increases oxidative 
stress, mitochondrial DNA damage, and many senescence-
associated phenotypes already present in untreated Akita 
diabetic mice. These studies raise important questions 
about the role of bradykinin in health and disease and the 
mechanism(s) of action of ACEIs. (J Clin Invest 2006; 116: 
1302–1309)
Juan Oliver
Influence of donor C3 allotype 
on late renal-transplantation 
outcome
The complement system has a critical role in both the innate 
and the adaptive immune responses. In humans, wherein 
complement C3 exists as two main allotypes, F (fast) and S 
Location of the C3F/S polymorphism in human complement 
component C3.  
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(slow), C3F has been associated with autoimmune diseases. 
In a study published in the New England Journal of Medicine, 
Brown et al. examined the infl uence of these alleles on late 
renal-graft outcome. Analysis of 513 pairs of white donors 
and recipients followed over a median 3.3 years showed that 
the C3F donor allele in the donor kidney was benefi cial in 
transplant recipients as compared to those donor kidneys 
that did not possess the allele. In this group of patients, 
graft survival was signifi cantly prolonged, fewer graft losses 
were attributed to chronic allograft nephropathy, and renal 
function was improved. Typing both donor and recipient 
for these polymorphisms may allow the identifi cation of 
patients at increased risk for adverse graft outcomes, with 
the possibility of either modifying immunosuppressive 
regimens or placing the patients under closer surveillance. 
(N Engl J Med 2006; 354: 2014–2023)
Jai Radhakrishnan
Sirolimus-associated pneumonitis 
in renal transplant recipients
Interstitial pneumonitis is a poorly defi ned side effect 
of sirolimus, for patients with solid-organ transplants. 
A study by Champion et al. evaluated the clinical and 
laboratory features of sirolimus-associated pneumonitis. In 
the case series at a transplantation center in Paris, France, 
24 patients who had renal transplantation and developed 
sirolimus-associated pneumonitis underwent withdrawal 
or a dose reduction of sirolimus. Common symptoms at 
presentation included cough, fatigue, fever, and dyspnea. 
Computed tomography of the chest showed reticular and 
ground-glass opacities, bronchiolitis obliterans-organizing 
pneumonia, and lobar consolidation. Bronchoalveolar 
lavage showed lymphocytic or eosinophilic alveolitis 
or pulmonary hemorrhage. A reduction in the dose 
of sirolimus improved symptoms in two patients, but 
discontinuation of drug therapy was eventually necessary 
in all patients. All patients recovered completely within 
6 months. (Ann Intern Med 2006; 144: 505–509)
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